CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.480
+0.060 (4.23%)
Jul 25, 2025, 4:00 PM - Market closed
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 233 employees as of December 31, 2024. The number of employees increased by 57 or 32.39% compared to the previous year.
Employees
233
Change (1Y)
57
Growth (1Y)
32.39%
Revenue / Employee
$134,627
Profits / Employee
-$173,734
Market Cap
22.93M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 233 | 57 | 32.39% |
Dec 31, 2023 | 176 | -48 | -21.43% |
Dec 31, 2022 | 224 | 48 | 27.27% |
Dec 31, 2021 | 176 | 32 | 22.22% |
Dec 31, 2020 | 144 | 19 | 15.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CASI News
- 5 days ago - CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - Accesswire
- 2 months ago - CASI Pharmaceuticals Provides Business and Clinical Update - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - Accesswire
- 2 months ago - CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - Accesswire
- 2 months ago - CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Accesswire
- 7 months ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire